Probiotic LA85 shows potential to curb antibiotic-related diarrhea :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

LA85 probiotic improves stool consistency and shortens antibiotic-associated diarrhea

Antibiotic-associated diarrhea Antibiotic-associated diarrhea
Antibiotic-associated diarrhea Antibiotic-associated diarrhea

What's new?

Lactobacillus acidophilus LA85 shortens diarrhea, stabilizes stools, and improves gut quality of life in younger adults, showing promise in preventing antibiotic-associated diarrhea.

According to the findings of a study, probiotic Lactobacillus acidophilus LA85 may help prevent antibiotic-associated diarrhea (AAD), with particularly strong benefits in adults under 53 years of age. A group of researchers conducted this randomized controlled trial to determine the efficacy and safety of LA85 in preventing amoxicillin-associated diarrhea, providing clinical evidence to support its role as a probiotic intervention.

This clinical trial enrolled 82 adults receiving amoxicillin therapy. Participants received either L. acidophilus LA85 (2 × 109 CFU/day) or a placebo for 14 days.

  • Primary outcomes included the incidence and duration of AAD and stool consistency, assessed using the Bristol Stool Form Scale (BSFS).
  • Secondary outcomes evaluated safety and gastrointestinal quality of life.

An exploratory subgroup analysis examined the response in younger adults (<53 years) to assess age-related differences in efficacy. LA85 supplementation exhibited benefits in managing AAD with a strong safety profile. It showed a tendency to lower AAD incidence, though the difference when compared to placebo was not statistically significant. Participants taking LA85 experienced shorter diarrhea episodes than those on placebo (p = 0.072), indicating a noticeable clinical benefit.

Those receiving LA85 maintained stable stool consistency (around 3.5), while placebo participants had greater variation (3.5–4.0), suggesting better digestive stability with the probiotic. Notably, subgroup analysis in participants under 53 years of age revealed a prominent reduction in AAD incidence (p = 0.008) and the complete elimination of persistent diarrhea episodes in those receiving LA85. Gastrointestinal quality of life scores also boosted markedly in the probiotic arm (p < 0.05).

Safety data were reassuring, with no severe adverse events reported, highlighting LA85 as a well-tolerated intervention. These findings support the potential role of LA85 as a preventive therapy for antibiotic-induced gut disturbances, especially in younger adults. However, larger-scale studies with longer follow-up and microbiome analysis are needed to validate these benefits and establish broader clinical guidelines.

Source:

Food Science & Nutrition

Article:

Efficacy and Safety of Lactobacillus acidophilus LA85 in Preventing Antibiotic-Associated Diarrhea: A Randomized, Placebo-Controlled Study

Authors:

Jianguo Zhu et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: